Literature DB >> 16452467

Relationship between UDP-galactose 4'-epimerase activity and galactose sensitivity in yeast.

Jamie Wasilenko1, Judith L Fridovich-Keil.   

Abstract

UDP-galactose 4'-epimerase (GALE) catalyzes the final step of the highly conserved Leloir pathway of galactose metabolism. Loss of GALE in humans results in a variant form of the metabolic disorder, galactosemia. Loss of GALE in yeast results in galactose-dependent growth arrest. Although the role of GALE in galactose metabolism has been recognized for decades, the precise relationship between GALE activity and galactose sensitivity has remained unclear. Here we have explored this relationship by asking the following. 1) Is GALE rate-limiting for galactose metabolism in yeast? 2) What is the relationship between GALE activity and galactose-dependent growth arrest in yeast? 3) What is the relationship between GALE activity and the abnormal accumulation of galactose metabolites in yeast? To answer these questions we engineered a strain of yeast in which GALE was doxycycline-repressible and studied these cells under conditions of intermediate GALE expression. Our results demonstrated a smooth linear relationship between galactose metabolism and GALE activity over a range from 0 to approximately 5% but a steep threshold relationship between growth rate in galactose and GALE activity over the same range. The relationship between abnormal accumulation of metabolites and GALE activity was also linear over the range from 0 to approximately 5%, suggesting that if the abnormal accumulation of metabolites underlies galactose-dependent growth-arrest in GALE-impaired yeast, either the impact of individual metabolites must be synergistic and/or the threshold of sensitivity must be very steep. Together these data reveal important points of similarity and contrast between the roles of GALE and galactose-1-phosphate uridylyltransferase in galactose metabolism in yeast and provide a framework for future studies in mammalian systems.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452467     DOI: 10.1074/jbc.M600778200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  Altered cofactor binding affects stability and activity of human UDP-galactose 4'-epimerase: implications for type III galactosemia.

Authors:  Thomas J McCorvie; Ying Liu; Andrew Frazer; Tyler J Gleason; Judith L Fridovich-Keil; David J Timson
Journal:  Biochim Biophys Acta       Date:  2012-05-18

2.  A Case Study of Monozygotic Twins Apparently Homozygous for a Novel Variant of UDP-Galactose 4'-epimerase (GALE) : A Complex Case of Variant GALE.

Authors:  Ying Liu; Kristi Bentler; Bradford Coffee; Juliet S Chhay; Kyriakie Sarafoglou; Judith L Fridovich-Keil
Journal:  JIMD Rep       Date:  2012-07-01

3.  Metabolic regulation of collagen gel contraction by porcine aortic valvular interstitial cells.

Authors:  Peter I Kamel; Xin Qu; Andrew M Geiszler; Deepak Nagrath; Romain Harmancey; Heinrich Taegtmeyer; K Jane Grande-Allen
Journal:  J R Soc Interface       Date:  2014-12-06       Impact factor: 4.118

4.  Distinct roles of galactose-1P in galactose-mediated growth arrest of yeast deficient in galactose-1P uridylyltransferase (GALT) and UDP-galactose 4'-epimerase (GALE).

Authors:  Jane Odhiambo Mumma; Juliet S Chhay; Kerry L Ross; Jana S Eaton; Karen A Newell-Litwa; Judith L Fridovich-Keil
Journal:  Mol Genet Metab       Date:  2007-11-05       Impact factor: 4.797

5.  In vivo and in vitro function of human UDP-galactose 4'-epimerase variants.

Authors:  Thomas J McCorvie; Jamie Wasilenko; Ying Liu; Judith L Fridovich-Keil; David J Timson
Journal:  Biochimie       Date:  2011-06-17       Impact factor: 4.079

Review 6.  Galactosemia: Towards Pharmacological Chaperones.

Authors:  Samantha Banford; Thomas J McCorvie; Angel L Pey; David J Timson
Journal:  J Pers Med       Date:  2021-02-07

7.  GALE Promotes the Proliferation and Migration of Glioblastoma Cells and Is Regulated by miR-let-7i-5p.

Authors:  Xiaopeng Sun; Hao Xue; Ye Xiong; Rui Yu; Xiao Gao; Mingyu Qian; Shaobo Wang; Huizhi Wang; Jianye Xu; Zihang Chen; Lin Deng; Gang Li
Journal:  Cancer Manag Res       Date:  2019-12-16       Impact factor: 3.989

8.  Toward repurposing ciclopirox as an antibiotic against drug-resistant Acinetobacter baumannii, Escherichia coli, and Klebsiella pneumoniae.

Authors:  Kimberly M Carlson-Banning; Andrew Chou; Zhen Liu; Richard J Hamill; Yongcheng Song; Lynn Zechiedrich
Journal:  PLoS One       Date:  2013-07-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.